Company intelligence / Profile preview
TimeBio
Suwon-si, Gyeonggi-do, Republic of Koreatimebio.co.kr ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
No clinical trial results published. The company is developing an exosome-based platform targeting skin aging from immune dysfunction, with commercialized cosmetic products already available.
- Therapeutic areas
- DermatologyImmunology
- Modalities
- Exosome-based drug delivery therapyImmune-enhancing adjuvant (Biologic)Small molecule (for cosmetics/hair products)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on TimeBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TimeBio.